House rejects amendments on Prescription Drug Affordability Board; bill advanced for third reading

The Maryland House of Delegates spent extensive floor time debating amendments to legislation concerning the Prescription Drug Affordability Board (PDAB) and the board’s authority to institute upper payment limits intended to lower prescription costs. Multiple amendments introduced by delegates sought additional guardrails around patient access, rare‑disease drugs, industry impacts and pharmacy protections; all were rejected by recorded votes or roll calls during the session segment.

Lawmakers discussed several recurring themes: the potential for upper payment limits to reduce patient access via formulary changes or supply shortages; the need for transparency and patient engagement before limits take effect; the possible impact on the state's life‑science and biotech sector; and protections for independent community pharmacies. The minority leader and multiple amendment sponsors urged safeguards, citing concerns that unilateral limits…